lamotrigine has been researched along with Body Weight in 40 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have performed a randomised, prospective study to compare the efficacy and tolerability of sodium valproate (VPA) and lamotrigine (LTG) monotherapy, and their effects on circulating androgenic hormones, in newly diagnosed epilepsy." | 9.12 | Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. ( Brodie, MJ; Butler, E; Hitiris, N; Leach, JP; Leach, VM; Parker, P; Sills, GJ; Stephen, LJ; Wilson, EA, 2007) |
| "The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium)." | 9.12 | Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. ( Bentley, B; Bowden, C; Calabrese, JR; Ketter, T; Sachs, G; Thompson, T; White, R, 2006) |
| "To compare the incidence and magnitude of change in body weight associated with lamotrigine or divalproex sodium monotherapy in patients with epilepsy." | 9.09 | Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. ( Barrett, PS; Biton, V; Hammer, AE; Mirza, W; Montouris, G; Vuong, A, 2001) |
| "To examine the population pharmacokinetics of lamotrigine in patients newly diagnosed with epilepsy and receiving oral lamotrigine monotherapy for up to 48 weeks." | 9.08 | Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. ( Hussein, Z; Posner, J, 1997) |
| " An important side effect associated with the long-term use of some antiepileptic drugs is change in body weight, followed by an increased risk for subsequent maturational problems in pediatric epilepsy patients." | 6.70 | Normal growth during lamotrigine monotherapy in pediatric epilepsy patients -- a prospective evaluation of 103 children and adolescents. ( Ueberall, MA, 2001) |
| "All the children had treatment-resistant epilepsy and most had two or more seizure types." | 6.68 | Lamotrigine for the treatment of epilepsy in childhood. ( Alving, J; Besag, FM; Dulac, O; Hosking, G; Spencer, SC; Wallace, SJ, 1995) |
| " The correlation with dose may be a spurious finding related to the fact that physicians, in adjusting dosage according to clinical response, are more likely to use larger doses in patients with high clearance values." | 5.43 | An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ( Alexandre, V; Baldoni, AO; de Santi Ferreira, FI; Freitas-Lima, P; Martinez, EZ; Pereira, LR; Perucca, E; Queiroz, RH; Sakamoto, AC, 2016) |
| "Status epilepticus was induced by electric stimulation of the perforant pathway (PP) in rats." | 5.31 | Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat. ( Halonen, T; Nissinen, J; Pitkänen, A, 2001) |
| "In the lithium/valproate study, modest increases in body weight were observed at Week 52 in both groups: 1." | 5.17 | Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. ( Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z, 2013) |
| "The extent of lamotrigine interactions was investigated dependent on age, gender, weight and dose of concomitant carbamazepine and/or valproic acid in 65 patients with epilepsy." | 5.16 | Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. ( Brzaković, BB; Martinović, ZJ; Miljković, BR; Pokrajac, MV; Prostran, MŠ; Vezmar Kovačević, SD; Vučićević, KM, 2012) |
| "We have performed a randomised, prospective study to compare the efficacy and tolerability of sodium valproate (VPA) and lamotrigine (LTG) monotherapy, and their effects on circulating androgenic hormones, in newly diagnosed epilepsy." | 5.12 | Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. ( Brodie, MJ; Butler, E; Hitiris, N; Leach, JP; Leach, VM; Parker, P; Sills, GJ; Stephen, LJ; Wilson, EA, 2007) |
| "Lamotrigine was effective and well tolerated and appeared to have no effect on body weight when given as monotherapy or as adjunctive therapy with valproate, antipsychotics, lithium, or antidepressants to outpatients with bipolar I disorder in a 12-week open-label study." | 5.12 | Effectiveness and weight effects of open-label lamotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder. ( Graham, J; Nanry, K; Roberts, J; Thompson, T; Zarzar, MN, 2007) |
| "The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium)." | 5.12 | Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. ( Bentley, B; Bowden, C; Calabrese, JR; Ketter, T; Sachs, G; Thompson, T; White, R, 2006) |
| "A post hoc analysis was conducted to assess the effects of lamotrigine, lithium, and placebo administration on body weight in obese and nonobese patients with bipolar disorder from two double-blind, placebo-controlled, 18-month studies." | 5.12 | Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. ( Bowden, CL; Calabrese, JR; Ketter, TA; Sachs, GS; Thompson, TR; White, RL, 2006) |
| "We reviewed 570 medical charts of outpatients 12 years and older seen at the Columbia Comprehensive Epilepsy Center who received lamotrigine as monotherapy or adjunctive therapy." | 5.11 | Effect of antiepileptic drug comedication on lamotrigine clearance. ( Buchsbaum, R; Hirsch, LJ; Resor, SR; Weintraub, D, 2005) |
| "To compare the incidence and magnitude of change in body weight associated with lamotrigine or divalproex sodium monotherapy in patients with epilepsy." | 5.09 | Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. ( Barrett, PS; Biton, V; Hammer, AE; Mirza, W; Montouris, G; Vuong, A, 2001) |
| "To examine the population pharmacokinetics of lamotrigine in patients newly diagnosed with epilepsy and receiving oral lamotrigine monotherapy for up to 48 weeks." | 5.08 | Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. ( Hussein, Z; Posner, J, 1997) |
| "The alterations observed in body composition with valproic acid in contrast to other AEDs like levetiracetam, carbamazepine and phenytoin could affect treatment response in epilepsy especially in subjects with already altered body composition status like obese and thin frail patients, which needs to be established by prospective studies (CTRI/2013/05/003701)." | 3.83 | Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs. ( Gupta, YK; Kakkar, AK; Sarangi, SC; Tripathi, M, 2016) |
| "several parameters, concerning fertility were measured in 40 albino male rats of Sprague Dawley strain, they were divided into 4 groups, group one received vehicle (distilled water), group two received Vigabatrin in a dose of 200 mg/kg body weight, group three received Lamotrigine in a dose of 30 mg/kg body weight, and group four received Gabapentin 100 mg/kg body weight." | 3.72 | The effect of Vigabatrin, Lamotrigine and Gabapentin on the fertility, weights, sex hormones and biochemical profiles of male rats. ( Abdul-Zahra, E; Bataineh, H; Daoud, AS; Otoom, S, 2004) |
| " To evaluate the effect of lamotrigine on body weight in adult patients with epilepsy, we conducted a retrospective review of data from 463 patients treated with lamotrigine in 32 clinical trials." | 3.70 | Stable weight during lamotrigine therapy: a review of 32 studies. ( Barrett, PS; Devinsky, O; Hammer, A; Vuong, A, 2000) |
| "The aim of this analysis was to describe the pharmacokinetics of oral lamotrigine (LTG) in Indian epileptic patients using a population pharmacokinetic (PPK) modeling approach to confirm that the PK is similar to that of the Caucasian population, and to evaluate and confirm the impact of covariates predictive of inter-individual variability using a simulation platform." | 2.78 | Population pharmacokinetics of lamotrigine in Indian epileptic patients. ( Arumugam, K; Bathala, L; Johnson, MG; Mallaysamy, S; Rajakannan, T; Ramakrishna, D; Rao, PG; van Hasselt, JG, 2013) |
| " The goal of this study is to determine the pharmacokinetic parameters, such as clearance, and the factors that have a significant effect on these parameters to provide evidence-based information that can be used to dose elderly patients taking lamotrigine." | 2.73 | Population pharmacokinetics of lamotrigine in elderly patients. ( Birnbaum, AK; Brundage, RC; Collins, JF; Macias, FM; Punyawudho, B; Ramsay, RE; Rowan, AJ, 2008) |
| " An important side effect associated with the long-term use of some antiepileptic drugs is change in body weight, followed by an increased risk for subsequent maturational problems in pediatric epilepsy patients." | 2.70 | Normal growth during lamotrigine monotherapy in pediatric epilepsy patients -- a prospective evaluation of 103 children and adolescents. ( Ueberall, MA, 2001) |
| "This analysis was performed to validate a previously developed population pharmacokinetic model for lamotrigine in order to establish a basis for dosage recommendations for children." | 2.69 | Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. ( Chen, C, 2000) |
| "All the children had treatment-resistant epilepsy and most had two or more seizure types." | 2.68 | Lamotrigine for the treatment of epilepsy in childhood. ( Alving, J; Besag, FM; Dulac, O; Hosking, G; Spencer, SC; Wallace, SJ, 1995) |
| "Lamotrigine (LTG) is a new antiepileptic drug (AED), chemically unrelated to the drugs in current use." | 2.68 | Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. ( Jürgens, U; May, TW; Rambeck, B, 1996) |
| "For clinical application, LTG maintenance dose could be optimized using population pharmacokinetic models employing covariates such as concomitant antiepileptic drugs, body weight, and genetic polymorphisms." | 2.66 | Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses. ( Leelakanok, N; Methaneethorn, J, 2020) |
| "Lamotrigine is a broad-spectrum antiepileptic drug with high interindividual variability in serum concentrations in children." | 1.62 | Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models. ( Aboura, R; Benaboud, S; Billette de Villemeur, T; Bouazza, N; Chenevier-Gobeaux, C; Desguerre, I; Freihuber, C; Gana, I; Hirt, D; Nabbout, R; Tauzin, M; Tréluyer, JM; Zheng, Y, 2021) |
| " cambogia extract and lamotrigine (LTG) through two independent pharmacokinetic studies." | 1.51 | Short-term effects of Garcinia cambogia extract on the pharmacokinetics of lamotrigine given as a single-dose in Wistar rats. ( Alves, G; Falcão, A; Rodrigues, M; Ventura, S, 2019) |
| " The aim of this study was to establish a PPK model of MHD to investigate the effects of genetic polymorphisms in UGT2B7, UGT1A9, ABCB1, and ABCB2 in adult Chinese patients with epilepsy and to develop a new dosage guideline for OXC." | 1.51 | Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis. ( Jiao, Z; Lin, RF; Lin, S; Lin, WW; Lin, XH; Wang, CL; Yu, XL; Zhang, J; Zhang, WB, 2019) |
| " In addition, simulations were performed to identify the implication of different doses and dosing regimens for each population, so as to ensure steady-state concentrations within a predefined reference range." | 1.48 | Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials. ( Danhof, M; de Jager, NCB; Della Pasqua, O; Rauwé, WM; van Dijkman, SC, 2018) |
| " In the first pharmacokinetic study, a single oral dose of C." | 1.48 | Evaluation of the effects of Citrus aurantium (bitter orange) extract on lamotrigine pharmacokinetics: Insights from in vivo studies in rats. ( Alves, G; Falcão, A; Rodrigues, M; Ventura, S, 2018) |
| " The correlation with dose may be a spurious finding related to the fact that physicians, in adjusting dosage according to clinical response, are more likely to use larger doses in patients with high clearance values." | 1.43 | An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ( Alexandre, V; Baldoni, AO; de Santi Ferreira, FI; Freitas-Lima, P; Martinez, EZ; Pereira, LR; Perucca, E; Queiroz, RH; Sakamoto, AC, 2016) |
| "Huntington's disease is a progressive neurodegenerative disorder that gradually reduces memory, cognitive skills and normal movements of affected individuals." | 1.38 | Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. ( Kalonia, H; Kumar, A; Kumar, P, 2012) |
| "Status epilepticus was induced by electric stimulation of the perforant pathway (PP) in rats." | 1.31 | Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat. ( Halonen, T; Nissinen, J; Pitkänen, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.00) | 18.2507 |
| 2000's | 18 (45.00) | 29.6817 |
| 2010's | 15 (37.50) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kamali, M | 1 |
| Johari, H | 1 |
| Hami, J | 1 |
| Methaneethorn, J | 1 |
| Leelakanok, N | 1 |
| Tauzin, M | 1 |
| Tréluyer, JM | 1 |
| Nabbout, R | 1 |
| Billette de Villemeur, T | 1 |
| Desguerre, I | 1 |
| Aboura, R | 1 |
| Gana, I | 1 |
| Zheng, Y | 1 |
| Benaboud, S | 1 |
| Bouazza, N | 1 |
| Chenevier-Gobeaux, C | 1 |
| Freihuber, C | 1 |
| Hirt, D | 1 |
| van Dijkman, SC | 1 |
| de Jager, NCB | 1 |
| Rauwé, WM | 1 |
| Danhof, M | 1 |
| Della Pasqua, O | 1 |
| Koneval, Z | 1 |
| Knox, KM | 1 |
| White, HS | 1 |
| Barker-Haliski, M | 1 |
| Galappatthy, P | 1 |
| Liyanage, CK | 1 |
| Lucas, MN | 1 |
| Jayasekara, DTLM | 1 |
| Abhayaratna, SA | 1 |
| Weeraratne, C | 1 |
| De Abrew, K | 1 |
| Gunaratne, PS | 1 |
| Gamage, R | 1 |
| Wijeyaratne, CN | 1 |
| Ventura, S | 2 |
| Rodrigues, M | 2 |
| Falcão, A | 2 |
| Alves, G | 2 |
| Lin, WW | 1 |
| Wang, CL | 1 |
| Jiao, Z | 1 |
| Yu, XL | 1 |
| Zhang, J | 1 |
| Zhang, WB | 1 |
| Lin, RF | 1 |
| Lin, S | 1 |
| Lin, XH | 1 |
| Simko, J | 1 |
| Fekete, S | 1 |
| Gradosova, I | 1 |
| Malakova, J | 1 |
| Zivna, H | 1 |
| Valis, M | 1 |
| Palicka, V | 1 |
| Zivny, P | 1 |
| Baldoni, AO | 1 |
| Freitas-Lima, P | 1 |
| de Santi Ferreira, FI | 1 |
| Martinez, EZ | 1 |
| Queiroz, RH | 1 |
| Sakamoto, AC | 1 |
| Alexandre, V | 1 |
| Perucca, E | 1 |
| Pereira, LR | 1 |
| Sarangi, SC | 1 |
| Tripathi, M | 1 |
| Kakkar, AK | 1 |
| Gupta, YK | 1 |
| Rauchenzauner, M | 1 |
| Griesmacher, A | 1 |
| Tatarczyk, T | 1 |
| Haberlandt, E | 1 |
| Strasak, A | 1 |
| Zimmerhackl, LB | 1 |
| Falkensammer, G | 1 |
| Luef, G | 1 |
| Högler, W | 1 |
| Ramadan, E | 1 |
| Basselin, M | 1 |
| Rao, JS | 1 |
| Chang, L | 1 |
| Chen, M | 1 |
| Ma, K | 1 |
| Rapoport, SI | 1 |
| Kumar, P | 1 |
| Kalonia, H | 1 |
| Kumar, A | 1 |
| Brzaković, BB | 1 |
| Vezmar Kovačević, SD | 1 |
| Vučićević, KM | 1 |
| Miljković, BR | 1 |
| Martinović, ZJ | 1 |
| Pokrajac, MV | 1 |
| Prostran, MŠ | 1 |
| Mallaysamy, S | 1 |
| Johnson, MG | 1 |
| Rao, PG | 1 |
| Rajakannan, T | 1 |
| Bathala, L | 1 |
| Arumugam, K | 1 |
| van Hasselt, JG | 1 |
| Ramakrishna, D | 1 |
| Kemp, DE | 1 |
| De Hert, M | 1 |
| Rahman, Z | 1 |
| Fyans, P | 1 |
| Eudicone, JM | 1 |
| Marler, SV | 1 |
| Baker, RA | 1 |
| Carlson, BX | 1 |
| Main, L | 1 |
| Mikulecká, A | 1 |
| Kubová, H | 1 |
| Mares, P | 1 |
| Daoud, AS | 1 |
| Bataineh, H | 1 |
| Otoom, S | 1 |
| Abdul-Zahra, E | 1 |
| Weintraub, D | 1 |
| Buchsbaum, R | 1 |
| Resor, SR | 1 |
| Hirsch, LJ | 1 |
| Schmitz, B | 1 |
| Bergmann, L | 1 |
| Sachs, G | 1 |
| Bowden, C | 1 |
| Calabrese, JR | 2 |
| Ketter, T | 1 |
| Thompson, T | 2 |
| White, R | 1 |
| Bentley, B | 1 |
| Bowden, CL | 1 |
| Ketter, TA | 1 |
| Sachs, GS | 1 |
| White, RL | 1 |
| Thompson, TR | 1 |
| Stephen, LJ | 1 |
| Sills, GJ | 1 |
| Leach, JP | 1 |
| Butler, E | 1 |
| Parker, P | 1 |
| Hitiris, N | 1 |
| Leach, VM | 1 |
| Wilson, EA | 1 |
| Brodie, MJ | 1 |
| Zarzar, MN | 1 |
| Graham, J | 1 |
| Roberts, J | 1 |
| Nanry, K | 1 |
| Punyawudho, B | 1 |
| Ramsay, RE | 1 |
| Macias, FM | 1 |
| Rowan, AJ | 1 |
| Collins, JF | 1 |
| Brundage, RC | 1 |
| Birnbaum, AK | 1 |
| Besag, FM | 1 |
| Wallace, SJ | 1 |
| Dulac, O | 1 |
| Alving, J | 1 |
| Spencer, SC | 1 |
| Hosking, G | 1 |
| May, TW | 1 |
| Rambeck, B | 1 |
| Jürgens, U | 1 |
| Hussein, Z | 1 |
| Posner, J | 1 |
| Frank, LM | 1 |
| Enlow, T | 1 |
| Holmes, GL | 1 |
| Manasco, P | 1 |
| Concannon, S | 1 |
| Chen, C | 2 |
| Womble, G | 1 |
| Casale, EJ | 1 |
| Devinsky, O | 1 |
| Vuong, A | 2 |
| Hammer, A | 1 |
| Barrett, PS | 2 |
| Isojarvi, JI | 2 |
| Tapanainen, JS | 1 |
| Biton, V | 1 |
| Mirza, W | 1 |
| Montouris, G | 1 |
| Hammer, AE | 1 |
| Hassel, B | 1 |
| Taubøll, E | 2 |
| Gjerstad, L | 2 |
| Røste, LS | 1 |
| Berner, A | 1 |
| Ueberall, MA | 1 |
| Halonen, T | 1 |
| Nissinen, J | 1 |
| Pitkänen, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures[NCT00113165] | Phase 3 | 244 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa[NCT00264615] | Phase 3 | 45 participants | Interventional | 2005-10-31 | Completed | ||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
1 review available for lamotrigine and Body Weight
| Article | Year |
|---|---|
Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses.
Topics: Anticonvulsants; Body Weight; Humans; Lamotrigine; Triazines | 2020 |
17 trials available for lamotrigine and Body Weight
| Article | Year |
|---|---|
Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Area Under Curve; Body Weight; Carbamazepine; Child | 2012 |
Population pharmacokinetics of lamotrigine in Indian epileptic patients.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Lamotrigine; Male; Middle | 2013 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug | 2013 |
Effect of antiepileptic drug comedication on lamotrigine clearance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Agents; Body Weight; Chi | 2005 |
[The use of lamotrigine in female patients].
Topics: Acne Vulgaris; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Body Composition; Body W | 2007 |
Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Body Weight; Double-Blind Method; Female; Humans; Inc | 2006 |
Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Body Weight; Comorbidity; Double-Blind Method; Humans; Lam | 2006 |
Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy.
Topics: Adolescent; Adult; Aged; Androgens; Androstenedione; Anticonvulsants; Body Mass Index; Body Weight; | 2007 |
Effectiveness and weight effects of open-label lamotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder.
Topics: Analgesics; Bipolar Disorder; Body Weight; Drug Therapy, Combination; Female; Humans; Lamotrigine; M | 2007 |
Population pharmacokinetics of lamotrigine in elderly patients.
Topics: Aged; Aged, 80 and over; Aging; Alcohol Drinking; Algorithms; Anticonvulsants; Body Weight; Double-B | 2008 |
Lamotrigine for the treatment of epilepsy in childhood.
Topics: Adolescent; Anticonvulsants; Body Weight; Child; Child, Preschool; Consumer Product Safety; Dose-Res | 1995 |
Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.
Topics: Adult; Age Factors; Anticonvulsants; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; D | 1996 |
Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Body Weight; Contraceptives, Oral, Hormonal; Databases, Fa | 1997 |
Lamictal (lamotrigine) monotherapy for typical absence seizures in children.
Topics: Adolescent; Age Factors; Anticonvulsants; Body Height; Body Weight; Child; Child, Preschool; Dose-Re | 1999 |
Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.
Topics: Adolescent; Anticonvulsants; Body Weight; Child; Child, Preschool; Drug Interactions; Female; Humans | 2000 |
Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Body Weight; Child; Epilepsy; Female; Humans; Lamotrigine; | 2001 |
Normal growth during lamotrigine monotherapy in pediatric epilepsy patients -- a prospective evaluation of 103 children and adolescents.
Topics: Adolescent; Anticonvulsants; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Epi | 2001 |
22 other studies available for lamotrigine and Body Weight
| Article | Year |
|---|---|
Protective Effect of Flax Seed on Brain Teratogenicity Induced by Lamotrigine in Rat Fetuses.
Topics: Animals; Anticonvulsants; Body Weight; Brain; Brain Cortical Thickness; Female; Fetus; Flax; Hippoca | 2020 |
Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models.
Topics: Adolescent; Anticonvulsants; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; | 2021 |
Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Algorithms; Body Weight; Child; Child, Preschool; | 2018 |
Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Algorithms; Body Weight; Child; Child, Preschool; | 2018 |
Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Algorithms; Body Weight; Child; Child, Preschool; | 2018 |
Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Algorithms; Body Weight; Child; Child, Preschool; | 2018 |
Lamotrigine-resistant corneal-kindled mice: A model of pharmacoresistant partial epilepsy for moderate-throughput drug discovery.
Topics: Animals; Anticonvulsants; Anxiety; Body Weight; Cornea; Disease Models, Animal; Dose-Response Relati | 2018 |
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine; | 2018 |
Evaluation of the effects of Citrus aurantium (bitter orange) extract on lamotrigine pharmacokinetics: Insights from in vivo studies in rats.
Topics: Animals; Anticonvulsants; Area Under Curve; Body Weight; Citrus; Half-Life; Herb-Drug Interactions; | 2018 |
Short-term effects of Garcinia cambogia extract on the pharmacokinetics of lamotrigine given as a single-dose in Wistar rats.
Topics: Animals; Anticonvulsants; Area Under Curve; Body Weight; Dietary Supplements; Garcinia cambogia; Hal | 2019 |
Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Asian People; Body Weight; Drug Monitor | 2019 |
The effect of topiramate and lamotrigine on rat bone mass, structure and metabolism.
Topics: Absorptiometry, Photon; Administration, Oral; Alkaline Phosphatase; Animals; Anticonvulsants; Biomec | 2014 |
An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy.
Topics: Adult; Anticonvulsants; Body Weight; Dose-Response Relationship, Drug; Drug Interactions; Drug Thera | 2016 |
Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Benzodiazepines; Body Composition; Body Water; Body Weight; Carbamazepine; C | 2016 |
Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children.
Topics: Anthropometry; Anticonvulsants; Body Composition; Body Height; Body Mass Index; Body Weight; Carbama | 2010 |
Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder.
Topics: Analysis of Variance; Animals; Arachidonic Acid; Autoradiography; Body Weight; Brain; Calcium Channe | 2012 |
Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity.
Topics: Amines; Animals; Body Weight; Brain; Catalase; Cyclohexanecarboxylic Acids; GABAergic Neurons; Gabap | 2012 |
This life.
Topics: Affective Symptoms; Antidepressive Agents; Bipolar Disorder; Body Weight; Humans; Lamotrigine; Patie | 2003 |
Lamotrigine does not impair motor performance and spontaneous behavior in developing rats.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Bod | 2004 |
The effect of Vigabatrin, Lamotrigine and Gabapentin on the fertility, weights, sex hormones and biochemical profiles of male rats.
Topics: Amines; Analgesics; Animals; Antimanic Agents; Body Weight; Cyclohexanecarboxylic Acids; Female; Fer | 2004 |
Stable weight during lamotrigine therapy: a review of 32 studies.
Topics: Adult; Body Weight; Epilepsy; Female; Humans; Lamotrigine; Male; Triazines | 2000 |
Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Electroencephalography; Epilepsy; Female; Humans; H | 2000 |
Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels.
Topics: Amino Acids; Animals; Anticonvulsants; Body Weight; Brain; gamma-Aminobutyric Acid; Glutamic Acid; H | 2001 |
Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats.
Topics: Administration, Oral; Animals; Anticonvulsants; Body Temperature; Body Weight; Female; Immunoenzyme | 2001 |
Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat.
Topics: Animals; Anticonvulsants; Body Temperature; Body Weight; Brain; Lamotrigine; Male; Memory Disorders; | 2001 |